KatherineTuttle University of Washington School of Medicine, Division of NephrologyUnited States

KatherineTuttle
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. Dr. Tuttle’s collective body of work has shaped the “pillars of therapy“ approach to chronic kidney disease and cardiovascular disease in a fundamental manner across the spectrum of scientific discovery, clinical trials, and population level implementation. She is chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology and a member of the Cardio-Kidney-Metabolic working group for the American Heart Association. She has chaired numerous national and international initiatives including the inaugural National Kidney Foundation-KDOQI Guideline for Diabetes and Chronic Kidney Disease, the American Diabetes Association Diabetes and Chronic Kidney Disease Consensus Conference, International Society of Nephrology - World Congress of Nephrology, and the Kidney Health Initiative. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington.
Upload Picture
https://storage.unitedwebnetwork.com/files/1099/6b7c2f0f557b979fe64bdf671fc5433d.jpg
First Name
Katherine
Last Name
Tuttle
Institution
Country.
United States

Friday, February 7, 2025

Time Session
2:15 p.m.
3:45 p.m.
Parminder KaurJudge Chair parminder.judge@ndph.ox.ac.ukUniversity of Oxford, UKUnited Kingdom
  • Cardiovascular-Kidney-Metabolic Syndrome: What Does it Mean?
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • GLP-1 RA in Kidney Disease: Beyond T2DM Control
    BeatrizFernandez-Fernandez Speaker Hospital Universitario Fundación Jimenez Díaz Spain
  • New Frontiers in CKD Therapy: Endothelin Receptor Antagonists
    Maria JoséSoler Romeo Speaker Hospital del Vall d´HebronSpain
  • Myocardial Infarction in Kidney Disease - What Should a Nephrologist Know?
    SydneyTang Speaker scwtang@hkucc.hku.hkHong Kong, China
  • Q&A
Amaltas B Hall B101A
AndreaViecelli Chair andrea.viecelli@health.qld.gov.auUniversity of QueenslandAustralia
  • Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)
    RajivAgarwal Oral Abstract Presenter United States
  • Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial
    KatherineTuttle Oral Abstract Presenter University of Washington School of Medicine, Division of NephrologyUnited States
  • Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
    BradRovin Oral Abstract Presenter The Ohio State UniversityUnited States
Auditorium Brahmkamal Hall

Saturday, February 8, 2025

Time Session
4:15 p.m.
5:15 p.m.
RobertoPecoits Filho Chair Arbor Research Collaborative for HealthUnited States
  • A Nephrologist Perspective on the Cardio-Kidney-Metabolic Syndrome
    JananiRangaswami Speaker Professor of Medicine, George Washington University School of MedicineUnited States
  • Optimizing CKD Management in the Context of Diabetes and Obesity
    RobertoPecoits Filho Speaker Arbor Research Collaborative for HealthUnited States
  • Combining Therapies for Cardio-Kidney-Metabolic Conditions: An Integrative Approach
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • Q&A
Champa Hall 304

Thursday, February 6, 2025

Time Session
11:30 a.m.
1:30 p.m.
KenarJhaveri Chair United States
ManishaSahay Chair India
MitchellRosner Chair Univeristy of Virginia HealthUnited States
  • Clinical Trials Overview: Focus on GLP1a, MRA, and SGLT2
    MaartenTaal Speaker University of NottinghamUnited Kingdom
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    MadhukarMisra Speaker misram@health.missouri.eduUniversity of Missouri Columbia, USAUnited States
  • Q and A
Neelkamal Hall 305